Source: Media Outreach
Headline: Parkway Pantai Introduces Precision Medicine To Customise Treatment Plans For Cancer Patients
Patientsto benefit from precision medicine and more accurate diagnostics in ParkwayPantai’s hospitals across AsiaAcquiredprecision medicine platform through 55 per cent stake in Angsana Holdings
SINGAPORE – Media OutReach – 12 October 2017 – Cancerpatients at Parkway Pantai’s hospitals in Singapore can now benefit frompersonalised treatment plans and more accurate diagnostics with the help ofcancer genomics testing.
Through Next Generating Sequencing(NGS) which can retrieve more comprehensive genetic information from tumourtissue, doctors are able to determine which drugs are more effective for thepatients.
Parkway Pantai is the only privatehealthcare provider in Singapore with in-house precision medicine capability.It brought precision medicine into its integrated suite of healthcare solutions,after buying a 55 per cent stake in Angsana Holdings Pte Ltd for a totalconsideration of S$9.3 million. The transaction which took place on 31 Julyfurther strengthens Parkway Pantai’s leading position as a global healthcareprovider.
“With Angsana Molecular andDiagnostics, we now have the molecular capabilities to customise medicaltreatment for each individual patient. Precision medicine enables doctors andpatients to make better informed decisions on how to manage diseases moreefficiently and safely,” says Dr Tan See Leng, Group Chief Executive Officerand Managing Director of Parkway Pantai.
Angsana operates two College ofAmerican Pathologists (CAP) accredited laboratories in Singapore and Hong Kong.Its key products include Non Invasive Prenatal Testing (NIPT), allergy testingand cancer genomics.
“We are committed to deliverhigh-performance and affordable molecular diagnostic services to tailortreatment to the needs and characteristics of individual patients,” says DrChris Tan, Chief Executive Officer and founder of Angsana Molecular &Diagnostics. “We are excited to work with Parkway Pantai’s vast network ofhealthcare facilities to meet the health demand of the Asian population.”
Plans are being formalised forParkway Pantai’s 14 hospitals in Malaysia to perform NIPT, in a collaborationbetween Pantai Premier Pathology and Angsana. NIPT – a molecular test whichdetects chromosomal abnormalities such as Trisomy 21 in the fetus through asimple blood-draw from the mother – will also be offered at Parkway Pantai’s 10hospitals and medical centres in India.
Parkway Pantai is one ofAsia’s largest integrated private healthcare groups operating in Singapore,Malaysia, India, China, Brunei and United Arab Emirates. For over 40years, its Mount Elizabeth, Gleneagles, Pantai and Parkway brands haveestablished themselves as the region’s best known brands in private healthcare,synonymous with best-in-class patient experience and outcomes.
Leveraging its global trackrecord for medical excellence and managing world-class hospitals, ParkwayPantai is committed to making a difference in people’s lives through excellentpatient care, steadily expanding its reach in markets where demand forquality care is strong and growing.
Parkway Pantai is a leadinghealthcare player in its home markets of Singapore, Malaysia and India and keygrowth markets of China and Hong Kong.
It is part of IHH Healthcare,one of the world’s largest healthcare groups by market capitalisation. IHHoperates more than 10,000 licensed beds across 50 hospitals in 10countries worldwide, offering the full spectrum of integrated healthcareservices from clinics to hospitals to quaternary care and a wide range ofancillary services including medical education.
In Singapore, Parkway Pantaiis the largest private healthcare operator with four JCI-accredited,multi-specialty tertiary hospitals – Mount Elizabeth Hospital, Mount ElizabethNovena Hospital, Gleneagles Hospital and Parkway East Hospital. It also ownsParkwayShenton, a large network of primary healthcare clinics and services,ParkwayHealth Radiology, ParkwayHealth Laboratory and Parkway College.
In Malaysia, Parkway Pantaiis the second largest private healthcare provider operating ten PantaiHospitals, four Gleneagles Hospitals and ancillary healthcare servicesincluding Pantai Integrated Rehab and Pantai Premier Pathology.
India is now its third homemarket following the acquisition of Continental and Global Hospitals in 2015.Today, Parkway Pantai has a network of 7 hospitals and 3 medical centres in thekey cities of Chennai, Bengaluru, Hyderabad, Kolkata and Mumbai.
Parkway Pantai also has morethan 20 patient assistance centres across the globe, providing patients withseamless patient care and a one-stop referral source to its hospitals andservices.
For moreinformation, please visit www.parkwaypantai.com.
About Angsana Molecular & Diagnostics
Angsana Molecular& Diagnostics specialises in developing premium molecular diagnosticassays, serving the following four medical areas that have the largest impactin Asian population: allergy and molecular allergology, fetal maternal health,molecular oncology and pharmacogenetics.
Through analysisof medical conditions at a molecular level, combined with clinical consultationby board-certified medical geneticists and sub-specialty trained pathologists,Angsana empowers clinicians and patients to make better informed clinicaldecisions and improve the quality of patient care.
Strategicallylocated in Asia with multi-laboratory operations in Singapore, Hong Kong andMalaysia, Angsana Molecular & Diagnostics is dedicated to serving the Asiancommunity with fast and more affordable services within easy reach.
For moreinformation, visit www.angsanadx.com.
Published and distributed with permission of Media-Outreach.com.